EGFR-Mutant NSCLC: Chemo-TKI Bests TKI.

Abstract excerpt

Findings from FLAURA2, a phase III trial, show that adding chemotherapy to osimertinib, the preferred standard of care for patients with EGFR-mutant non-small cell lung cancer, significantly boosts progression-free survival. Serious side effects are also more likely with the combination, though, so patients should weigh the risk-benefit ratio.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aniline Compounds
• Share to Carcinoma, Non-Small-Cell Lung
• Share to ErbB Receptors